Can China and the U.S. work together to cure cancer?
Illustration by Sam Ward
In the early afternoon of June 5, 2017, at the annual American Society of Clinical Oncology (ASCO) conference, hundreds of the world’s leading cancer researchers, pharmaceutical firms and biotech investors focused their attention on a virtually unknown Chinese firm called Legend Biotech.
At that time, the U.S. company Johnson & Johnson’s $10.6 billion research and development budget amounted to $3 billion more than all Chinese pharmaceutical firms combined. But despite hailing from a
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Confidential documents show that Xiao Jianhua, a corrupt investor tied to China’s political elite, backed the country’s most successful and revered entrepreneur.
The Chinese politics expert discusses how Xi Jinping’s anti-corruption drive upset the Party’s equilibrium and signs of splintering within the leader’s ruling faction.
Navigate China's Business Landscape with Confidence.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy